Gastro-oesophageal reflux disease: A pharmacist's perspective for 2020

N. Schellack*, G. Schellack, J. C. Meyer, L. Malan, Q. Labuschagne, N. Nxumalo, K. Kupa

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Gastro-oesophageal reflux disease (GORD) produces symptoms that cause great irritation and discomfort to the patient. Pharmacotherapeutic management is directed at minimising these symptoms and reducing the causative factors, e.g. acid production, thereby providing the necessary relief. Currently available agents include simple antacids and acid suppression therapy, including histamine-2 receptor antagonists, proton-pump inhibitors, mucosal or cytoprotective agents and pro-motility agents. Deciding on appropriate therapy will be dependent upon the diagnosis, side-effects and cost-effectiveness of the treatment.

Original languageEnglish
Pages (from-to)31-37
Number of pages7
JournalSA Pharmaceutical Journal
Issue number3
Publication statusPublished - Sept 2020


  • Cytoprotective agents
  • GORD
  • Gastro-oesophageal reflux disease
  • Histamine-2 receptor antagonists
  • PPIs
  • Proton-pump inhibitors


Dive into the research topics of 'Gastro-oesophageal reflux disease: A pharmacist's perspective for 2020'. Together they form a unique fingerprint.

Cite this